| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2795955 | Cytokine | 2006 | 5 Pages |
Abstract
Leflunomide was clinically efficacious in this group of long standing resistant RA in an open study “real life” design. These results comply with those reported in previous clinical trials. Serum MMP-1, MMP-3, IL-10 and IL-6 levels decreased significantly. Despite high withdrawal rate, no serious adverse effects were recorded.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Endocrinology
Authors
Irena Litinsky, Daphna Paran, David Levartovsky, Irena Wigler, Ilana Kaufman, Ilana Yaron, Michael Yaron, Dan Caspi, Ori Elkayam,